mDETECT develops a DNA-methylation-based liquid biopsy technology that enables oncologists to accurately assess tumor burden and monitor treatment response in metastatic breast cancer patients. This technology provides detailed, personalized data on cancer progression and relapse, facilitating more effective patient management.
Funding
$120K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Monitoring tumor burden and treatment response in metastatic breast cancer patients often relies on invasive biopsies, which can be painful, costly, and may not accurately represent the entire tumor landscape. Current methods may also lack the sensitivity to detect minimal residual disease or early signs of relapse.
Solution
mDETECT offers a DNA-methylation-based liquid biopsy technology designed to provide a comprehensive assessment of tumor burden and treatment response in metastatic cancer patients. By analyzing methylation patterns in circulating tumor DNA, the technology aims to deliver detailed, personalized data on cancer progression and relapse. This non-invasive approach enables oncologists to gain insights into the dynamics of the disease, facilitating more informed treatment decisions and improved patient management. The liquid biopsy provides a less invasive and potentially more representative snapshot of the tumor's characteristics compared to traditional tissue biopsies.
Target Audience
The primary target audience includes oncologists specializing in metastatic breast cancer and other metastatic cancers, as well as hospitals and cancer centers that manage patients with advanced-stage malignancies.
Features
- DNA-methylation analysis of circulating tumor DNA (ctDNA)
- Non-invasive monitoring of tumor burden
- Assessment of treatment response
- Detection of minimal residual disease
- Early detection of relapse
- Personalized data on cancer progression